ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2
Abstract Epidermal growth factor receptor (EGFR) mutations are common in non-small-cell lung cancer (NSCLC) but typically confer poor responses to immunotherapy, likely owing to an inhibitory tumor immune microenvironment. Here, Rho-associated coiled-coil containing protein kinase 1 (ROCK1) was identified as...
